Request a demo specialized to your need.
Biopharma remains one of the most important contributors to global health innovation. However, the changing scenario with rising R&D costs, increasingly complex regulatory landscapes, and intensified competition necessitates new strategies in biopharma companies to remain competitive and innovative. Insights into such change by McKinsey focus on digital tools and data-driven methods at the core while giving an equal role to changes at organizational structure. The improvement in efficiency in R&D, the reduction in time to market, and the enhancement in standards for patient outcome are then realized by the companies that embrace these transformations.
The Pressing Need for Transformation
However, this increase in investment has been associated with a decline in R&D productivity in biopharma: in 2020, the mean development cost for a novel drug stood at $2.6 billion, more than double the average of $1.2 billion recorded in 2010, while return on that investment in drug development crashed from 10.1% in 2010 to a mere 1.8% in 2020. This growing disparity underscores the urgency for biopharma companies to transform their R&D practices at scale.
Digital Tools for Accelerating R&D
Digital transformation is what will enable the future of biopharma R&D: streamlined processes, quicker clinical trials, and better decision-making.
-
AI and Machine Learning: Of late, artificial intelligence and machine learning have been one of the most transformational tools in drug discovery and development. AI-driven platforms make early-stage drug discovery four times faster than the old process, thus increasing the speed in identifying potential candidates for development. One such AI platform identified a novel fibrosis drug candidate in 46 days, whereas the manual process used to take years.
-
Real-World Data (RWD): RWD integration in clinical trials sets a perspective on drug efficacy in the real world. One study has demonstrated that RWD decreases time to trial completion by 14% because of the fast patient recruitment and better designing of trials.
-
Automation: The automation of routine tasks in the clinical trials yields efficiency. It also reduces errors, enhances the accuracy of data, and allows researchers to deal with more serious and important issues.
The Rise of Decentralized Clinical Trials (DCTs)
Decentralized clinical trials, utilizing digital health technologies to enable patients to partake in a study outside of a clinical setting, have been taking off. They were accelerated by the COVID-19 pandemic, with DCTs rising by 77% between 2020 and 2022. They not only prove to be cost-effective but also enhance diversity among the patients recruited and are quicker in recruitment.
-
Patient Recruitment: DCTs allow the reach of enrollment to people who were not served before. DCTs reduce time to patient recruitment by about 30%, and even more in rare disease trials.
-
Cost Efficiency: DCTs can save up to 20% of trial costs compared to traditional site-based trials.
Breaking Down Organizational Silos
The traditional R&D structure in biopharma is fully siloed, where teams still work independently of one another. That kind of structuring is turning out to be a thing of the past. An integrated, cross-functional structure can effectively streamline processes and create an environment where collaboration can take place. Biopharma companies that adopt a collaborative model can reduce R&D timelines by 20%.
The Role of Advanced Analytics
Big Data and Advanced Analytics have become a set of technologies without a replacement in the armory of biopharma R&D. The technologies help companies analyze large pools of data for trend identification, trial design optimization, and prediction of patient outcomes. On average, companies that leverage advanced analytics in their R&D operations have reduced time-to-market by six months.
Investment in Talent and Cultural Transformation
It's not just about technology; transforming biopharma R&D also needs an update on culture and talent. Biopharma companies that invest in upskilling their workforce see a 30% lift in R&D productivity.
The future of biopharma R&D will be in the power of transformation: Digital technologies, decentralized trials, and collaboration will change the game for companies seeking ways to reap major efficiencies out of R&D. Companies that undergo this transformation will significantly enhance their competitiveness and become a force to be reckoned with in the future of health.
Cloudbyz Unified eClinical Platform is a comprehensive and integrated solution designed to streamline clinical trial operations. Built on the Salesforce cloud platform, our solution provides real-time visibility and analytics across study planning, budgeting, start-up, study management, data collection and management, safety management and finally close-out. With features like automated workflows, centralized data management, and seamless collaboration, Cloudbyz eClinical can help you achieve greater efficiency, compliance, and quality in your clinical operations. Contact us today to learn more about how Cloudbyz eClinical can help your organization optimize its clinical trial management processes.
To know more about Cloudbyz Unified eClinical Platform contact info@cloudbyz.com.
We have been positioned as a 'Major Contender' in the Everest Group's 2024 Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix® Assessment (link). This acknowledgment underscores the robustness of our solution and highlights the growing influence we're establishing within the industry.
Sources:
- McKinsey Report on Transforming biopharma R&D at scale
- Deloitte Report on Drug Development Costs
- Insilico Medicine AI Platform Case Study
- FDA Study on RWD
- McKinsey 2023 R&D Automation Report
- Tufts Center for the Study of Drug Development 2024 Report
- National Institutes of Health Study on DCT Costs
- IQVIA Advanced Analytics Study
- PwC R&D Productivity Report
Subscribe to our Newsletter
